Log in to save to my catalogue

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast...

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2266274278

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

About this item

Full title

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2019-08, Vol.20 (8), p.1124-1135

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundTrastuzumab duocarmazine is a novel HER2-targeting antibody–drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour activity in various models. In this first-in-human study, we assessed the safety and activity of trastuzumab duocarmazine in pa...

Alternative Titles

Full title

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2266274278

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2266274278

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(19)30328-6

How to access this item